Profile | GDS2987 / GI_42659228-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 13.8 | 44 |
GSM215244 | HMVEC_vehicle_rep2 | 30.7 | 58 |
GSM215253 | HMVEC_vehicle_rep3 | 18 | 50 |
GSM215254 | HMVEC_atorvastatin_rep1 | 1.7 | 5 |
GSM215282 | HMVEC_atorvastatin_rep3 | 6.3 | 15 |
GSM215344 | HMVEC_atorvastatin_rep2 | 11 | 27 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 18.9 | 35 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 28.6 | 49 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | ||
GSM215294 | HMVEC_SLx2119_rep1 | 23.9 | 60 |
GSM215295 | HMVEC_SLx2119_rep2 | 35 | 56 |
GSM215296 | HMVEC_SLx2119_rep3 | 8.5 | 14 |
GSM215297 | PASMC_vehicle_rep1 | 3.6 | 6 |
GSM215298 | PASMC_vehicle_rep2 | ||
GSM215310 | PASMC_vehicle_rep3 | 14.9 | 24 |
GSM215311 | PASMC_atorvastatin_rep1 | 8.7 | 15 |
GSM215312 | PASMC_atorvastatin_rep2 | 21.9 | 34 |
GSM215313 | PASMC_atorvastatin_rep3 | 35.9 | 47 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 21 | 34 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 36.7 | 56 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 12.2 | 21 |
GSM215327 | PASMC_SLx2119_rep1 | 21.5 | 36 |
GSM215328 | PASMC_SLx2119_rep2 | 40.5 | 57 |
GSM215329 | PASMC_SLx2119_rep3 | 11.9 | 23 |
GSM215330 | Fibroblasts_vehicle_rep1 | 22.1 | 45 |
GSM215331 | Fibroblasts_vehicle_rep2 | 31.7 | 60 |
GSM215332 | Fibroblasts_vehicle_rep3 | 20 | 53 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 30.9 | 60 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 38.4 | 64 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 38.1 | 62 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 27.8 | 61 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 5 | 16 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 44 | 67 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 45.8 | 68 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 43.9 | 67 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 34.9 | 61 |